ANAVEX LIFE SCIENCES CORP.
Anavex Life Sciences Corp. (NASDAQ: AVXL) is a clinical-stage biopharmaceutical company focused on developing differentiated therapeutics for central nervous system diseases with high unmet medical need. The company applies precision medicine approaches and genomic analysis to identify biomarkers that inform its… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What ANAVEX LIFE SCIENCES CORP. does
In the company’s own words
Anavex Life Sciences Corp. (NASDAQ: AVXL) is a clinical-stage biopharmaceutical company focused on developing differentiated therapeutics for central nervous system diseases with high unmet medical need. The company applies precision medicine approaches and genomic analysis to identify biomarkers that inform its clinical development programs. More information about the company is available at www.anavex.com.
The company's primary development focus centers on ANAVEX®2-73 (blarcamesine), a sigma-1 receptor agonist being evaluated across multiple indications including Alzheimer's disease, Parkinson's disease dementia, and Rett syndrome. ANAVEX®2-73 is formulated as an oral once-daily capsule for neurodegenerative diseases and as an oral liquid once-daily formulation for rare diseases. The company's secondary clinical program, ANAVEX®3-71, represents a novel mechanism combining sigma-1 receptor activation with M1 muscarinic allosteric modulation and is being developed for frontotemporal dementia, schizophrenia, and Alzheimer's disease. The company also maintains preclinical and early-stage programs including ANAVEX®1-41, ANAVEX®1066 for neuropathic and visceral pain, and ANAVEX®1037 for oncology applications.
Anavex's therapeutic approach centers on restoring cellular homeostasis through sigma-1 receptor activation, targeting diseases characterized by chronic cellular stress and protein aggregation. The company has received multiple regulatory designations including Orphan Drug Designation and Fast Track status for Rett syndrome, and Orphan Drug Designation for ANAVEX®3-71 in frontotemporal dementia. In November 2024, Anavex submitted a Marketing Authorization Application to the European Medicines Agency for blarcamesine in Alzheimer's disease treatment.
The company's pipeline addresses significant market opportunities across neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease affecting millions of Americans, Parkinson's disease affecting over ten million people worldwide, and rare genetic conditions like Rett syndrome and Fragile X syndrome. Anavex employs a precision medicine strategy incorporating genomic biomarkers to identify patient populations most likely to respond to treatment, differentiating its approach within the competitive CNS therapeutics landscape.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- NEW YORK, NY
- Fiscal year end
- September
- CIK
- 1314052
- SIC
- 2836
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns ANAVEX LIFE SCIENCES CORP. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · ANAVEX LIFE SCIENCES CORP.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do ANAVEX LIFE SCIENCES CORP. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of ANAVEX LIFE SCIENCES CORP.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in ANAVEX LIFE SCIENCES CORP.'s last four quarterly filings that the numbers alone won't show?”